Best Life Sciences Companies in Northern Ireland, United Kingdom
The 50 best Life Sciences companies in Northern Ireland, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sisaf.
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
Ranked: Best Life Sciences companies in Northern Ireland
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sisaf Provider of drug delivery nano silicon-based drug delivery systems | $33M | 68 mo ago | 18 18 → 17 (-6%) | Suzanne Siebert Founder & CEO | Series B | Top 50M | 95 patents Silicon-based drug delivery platforms and therapeutic formulation technologies | — |
| 2 | Cirdan Imaging Laboratory Information System for clinical laboratories 53Product top 30%Growth top 31%Moat top 37%Talent top 38% All 12 signals ▾Producttop 30% Growthtop 31% Moattop 37% Talenttop 38% Fundingtop 39% Fin. healthtop 45% Techbottom 47% Marketbottom 46% Globalbottom 45% Innovationbottom 44% Patentsbottom 33% Newsbottom 20% Product: 4 distinct product lines · Company stage: Series B Growth: Revenue +39% YoY · Web rank 50,000,000 → 10,000,000 YoY rank vs industry peers · Fliar Intelligence Index 53/100 | $24M | 3 mo ago | 84 | Cahal Cormican Co-Founder | Series B | Top 10M | 6 patents Medical imaging hardware for cabinet x‑ray specimen analysis and mammographic breast screening | — |
| 3 | B-Secur Platform offering security and authentication solutions | $18M | 36 mo ago | 70 70 → 37 (-47%) | Alan Foreman Co-Founder & CEO | Series B | Top 50M | 36 patents Wearable biometric monitoring devices for human and animal health diagnostics | 1 launch |
| 4 | Neurovalens Developer of non-invasive neurostimulation products | $18M | 11 mo ago | 22 22 → 29 (+32%) | Anthony Rober Wilcox Executive Director | Series A | Top 10M | 18 patents Non‑invasive vestibular nerve stimulation devices for anxiety, sleep and post‑COVID therapy | — |
| 5 | Re-Vana Therapeutics Developer of drug delivery platform forophthalmic diseases | $17M | 44 mo ago | 1 | Michael O’Rourke CEO | Series A | — | 27 patents Biodegradable ocular drug‑delivery implants and compositions for eye therapeutics | — |
| 6 | Cumulus Neuro AI and cloud-based brain physiology analysis tool for clinical trials 62Growth top 20%Funding top 30%News top 33%Moat top 39% All 7 signals ▾Growthtop 20% Fundingtop 30% Newstop 33% Moattop 39% Talentbottom 49% Marketbottom 47% Globalbottom 39% Growth: Headcount 21 → 41 (+95%) across vintages · Fresh capital in last 24 mo Funding: Raised $15.2M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $15M | 13 mo ago | 41 41 → 35 (-15%) | Brian Murphy Co-Founder & Chief Scientific Officer | Series A | — | — | — |
| 7 | Gendel Limited Ultrasound and electric field technology for solid tumour treatment | $6M | 294 mo ago | — | Les Russell CEO | Deadpooled | — | 5 patents Medical ultrasound therapy and tissue ablation device technologies. | — |
| 8 | CV6 Therapeutics Developer of combination therapies for the treatment of cancer | $6M | 45 mo ago | 6 | — | Series A | Top 10M | 65 patents Hydantoin-based deoxyuridine triphosphate (dUTP)ase inhibitors for cancer therapy | — |
| 9 | Axis Three Aesthetic consultation by providing 3D patient simulation | $5M | 205 mo ago | 11 | Steve Crummey CEO | Deadpooled | — | — | — |
| 10 | Causeway Sensors Nano-sized sensing chips for detection of early stage cancer | $5M | 55 mo ago | 5 | — | Seed | — | 20 patents High‑throughput multi‑well bioassay analysis and nanostructured plasmonic biomarker sensors. | — |
| 11 | Overwatch Research Online platform for clinical trial data and workflow management | $4M | 58 mo ago | 6 | Paul Wilsdon Co-Founder | Acquired | — | — | — |
| 12 | StimOxyGen Developer of therapeutics for cancer treatment | $4M | 13 mo ago | — | Tony McHale Co-Founder | Seed | — | — | — |
| 13 | Sonrai Analytics Developer of software for data analytics and ingishts | $4M | 11 mo ago | 16 16 → 31 (+94%) | Darragh Mcart Co-Founder & CEO | Seed | Top 50M | — | — |
| 14 | Dia Beta Labs Developer of novel therapeutic peptides for metabolic disease treatment | $4M | 13 mo ago | — | Nigel Irwin Co-Founder | Seed | — | — | — |
| 15 | Intelesens Provider of defibrillation and ECG electrodes for vital signs monitoring | $3M | 135 mo ago | 30 | — | Acquired | — | 14 patents Patents concentrated in health & consumer products | — |
| 16 | ProAxsis Developer of diagnostic test for the detection of respiratory conditions | $2M | 13 mo ago | 12 12 → 7 (-42%) | David Ribeiro CEO | Acquired | — | — | — |
| 17 | GenoME Diagnostics Developer of an in-vitro diagnostic test for ovarian cancer | $2M | 41 mo ago | 2 | Shannon Beattie CEO | Seed | — | — | — |
| 18 | Modius Health Device for weight loss | $2M | 105 mo ago | 21 | Jason McKeown Founder & CEO | Seed | — | — | — |
| 19 | PathXL Develops web-based workflow solutions for digital pathology | $1M | 164 mo ago | 30 | Des Speed ex-CEO | Acquired | — | 25 patents Digital pathology image analysis and tissue recognition with artifact correction and normalization | — |
| 20 | 42Genetics Provider of a platform for NGS data analysis | $1M | 65 mo ago | 2 | — | Seed | — | — | — |
| 21 | VascVersa Developer of cell therapies for vascular regeneration | $951K | 48 mo ago | 3 | Christina Neill Founder & CEO | Seed | — | 2 patents Formulating specialized cell culture media for bioproduction and research applications. | — |
| 22 | Biomarx Developer of automated diagnostic systems for molecular testing at point of care 24Funding top 46%Talent bottom 49%Global bottom 33% All 3 signals ▾Fundingtop 46% Talentbottom 49% Globalbottom 33% Funding: Raised $942k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $942K | 7 mo ago | — | Sean Macfarlane Founder | Seed | — | — | — |
| 23 | Covance Laboratories Developer of therapeutics for multiple diseases | $457K | 115 mo ago | — | Mike Bolinder CEO | Funding Raised | — | — | — |
| 24 | SignaCor Developer of therapeutics for cardiac diseases | $334K | 5 mo ago | — | Chris Watson Founder & CEO | Seed | — | — | — |
| 25 | Xenobics Diagnostic kits and reagents for food safety application | $207K | 105 mo ago | — | Brian Green Co-Founder | Deadpooled | — | — | — |
| 26 | Autism Biotech Biochemical test for the early diagnosis of autism | $51K | 96 mo ago | — | Suzanne Saffie-Siebert Co-Founder | Deadpooled | — | 6 patents Autism biomarkers for diagnostic and therapeutic applications | — |
| 27 | AMPLY Discovery Provider of AI-based infectious disease drug discovery platform | $20K | 5 mo ago | 2 | Chris Creevey Co-Founder | Seed | — | — | 1 job opening |
Top 12 Life Sciences companies in Northern Ireland
#1
Series B · Lisburn, Northern Ireland · founded 2010 · 84 employees$23.6Mraised▾
Cirdan Imaging designs manufactures and supplies medical imaging & informatics technology for the medical diagnosis and treatment of cancer. The company offers VividPath, a PACS image acquisition and viewer workstation to acquire, view, annotate, report, and store images in a database. Also provides gross specimen macro imaging systems for pathology laboratories; digital microscope cameras to support live onscreen review and image capture of slides; and medical imaging software solutions. The company has additional offices in Canada and Australia and offers products through a network of distributors in Europe, the Middle East, and Africa.
- Apr 2026Series B$4M
- Apr 2026Venture Debt$5.4M
- Oct 2024Series B$9.8M
- Oct 2023Series A$2.8M
#2
Series A · Belfast, Northern Ireland · founded 2013 · 22 employees$18Mraised▾
Developer of non-invasive neurostimulation products. The company is developing an electronic headset which include Stimu Slim, a small headset-like medical device that targets an area of the brain known to suppress appetite and induces a metabolic shift within the nervous system.
- Aug 2025Series A$8.1M
- Apr 2024Series A$2.7M
- Dec 2021Grant (prize money)$299.4K
- Jul 2020Series A$6.4M
#3
Series A · Belfast, Northern Ireland · founded 2015 · 41 employees$15.2Mraised▾
AI and cloud-based brain physiology analysis tool for clinical trials. It has a cloud-based platform and device that provides a next generation integrated physiological and digital biomarker platform that has the ability to perform assesment tests, analyse results, real-time data collection, and more for drug discovery.
- Jul 2025Series A$4.4M
- May 2021Series A$8.3M
- Oct 2020Grant (prize money)$237.8K
- Jul 2020Series A$1.4M
#4
Seed · Belfast, Northern Ireland · founded 2018 · 16 employees$3.6Mraised▾
Developer of software for data analytics and insights. The platform is offering AI and ML-based applications which enables users to filter and analyze data sets in real-time to provide results, predictions, or insights based on the analysis for precision medicine. It offers features such as data management, design workflows, data visualization, and many more.
- Sep 2025Seed—
- Nov 2022Seed—
- Jun 2022Seed$2.7M
- Mar 2020Seed$895.5K
#5
Seed · Londonderry, Northern Ireland · founded 2021$4Mraised▾
Developer of therapeutics for cancer treatment. It offers oxygen-generating nanoparticles that dissolve in acidic tumor environments to release oxygen and countering tumor hypoxia and improving the efficacy of radiotherapy and immunotherapy. It offers a lead candidate SGEN-33 designed to enhance radiotherapy outcomes by alleviating hypoxic resistance.
- Jun 2025Seed$2M
- Mar 2025Grant (prize money)—
- Mar 2025Seed$1.9M
#6
Seed · Belfast, Northern Ireland · founded 2025$941.9Kraised▾
Developer of automated diagnostic systems for molecular testing at point of care. The company provides a system that streamlines the diagnostic workflow. It offers a platform combining single-use cartridges with screen-printed electrodes. The system aims to decentralise diagnostic services and expand patient access to testing.
- Jan 2026Grant (prize money)—
- Jan 2026Seed$941.9K
#7
Seed · Belfast, Northern Ireland · founded 2022$3.5Mraised▾
Developer of novel therapeutic peptides for metabolic disease treatment. The company focused on developing novel therapeutic agents for metabolic diseases, particularly targeting the progressive decline of pancreatic beta-cell health in diabetes and obesity. They emphasize peptide analogues that are enzyme resistant, receptor selective, and highly soluble for better formulation. It aims for treatments that offer more sustainable, quality weight loss and better management of disease progression compared to current options.
- Jun 2025Seed$2M
- Jan 2025Grant (prize money)—
- Jan 2025Seed$1.5M
- Oct 2024Grant (prize money)$32.9K
#8
Acquired · Belfast, Northern Ireland · founded 2013 · 12 employees$2.2Mraised▾
Developer of diagnostic test for the detection of respiratory conditions. The company has developed ProteaseTags (active neutrophil elastase immunoassay), which have the capacity to rapidly and selectively bind active proteases. It quantifies the activity of a single protease species within a complex biological sample. They offer services including clinical research services, biomarkers, academic supports, etc.
- Jul 2025Seed$298.6K
- Apr 2024Seed$2.2M
- Feb 2023Conventional Debt$599.8K
- Mar 2015Grant (prize money)$54.3K
#9
Seed · Belfast, Northern Ireland · founded 2024$333.9Kraised▾
Developer of therapeutics for cardiac diseases. It offers a patented low-dose 5-aza therapy that harnesses DNA methylation to address multiple underlying causes of symptomatic hypertrophic cardiomyopathy including established fibrosis a key driver of disease progression.
- Mar 2026Seed$333.9K
#10
Series B · Belfast, Northern Ireland · founded 2014 · 70 employees$18.2Mraised▾
Platform offering security and authentication solutions. It provides tools to help organizations verify identities, manage access, and protect sensitive data. The platform supports workflows related to safeguarding user information and ensuring secure authentication processes.
- Jul 2023Series B—
- Nov 2021Series B$3M
- Sep 2020Series A$1.9M
- May 2020Series A$2.2M
#11
Series A · Belfast, Northern Ireland · founded 2015 · 1 employees$16.8Mraised▾
Developer of drug delivery platform for ophthalmic diseases. The company platform is meant for chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma. It offers a flagship product EyeLief, is a photo cross-linked sustained-release biodegradable implant delivering both biologic and small molecule drugs .
- Nov 2022Series A$11.9M
- 2020Seed$2.1M
- Jun 2020Seed$1.2M
- 2017Seed$1.6M
#12
Series B · Belfast, Northern Ireland · founded 2006 · 18 employees$32.6Mraised▾
Provider of drug delivery nano silicon-based drug delivery systems. It develops nano silicon particles for medicines, cosmetics, and nutraceuticals. Its platform uses elemental silicon particles with a honeycomb pore structure that allows controlled drug loading, targeting, and release. It also develops cosmeceuticals or nutraceuticals under the product name.
- Nov 2020Series B$13.2M
- Jul 2019Series A$3.8M
- Aug 2018Series A—
- May 2018Series A$4.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United Kingdom
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,508 United Kingdom-affiliated papers.
- Imperial College London70
- University College London67
- University of Cambridge54
- University of Edinburgh54
- University of Oxford48
- Gene4→31
- Population1→15
- Mutation1→13
- Chromatin1→11
- Mutant2→12
- Gene2→35
- Antimicrobial1→22
- Bacteria1→17
- Downregulation and upregulation1→17
- Antibody3→19
- Production (economics)3→14
- Antimicrobial4→14
- Agriculture9→18
- Sustainability1→10
- Food safety2→11
Where biotechnology is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United Kingdom
United Kingdom biotechnology patent filing is accelerating — 35,956 filings from 8,000 assignees (2016–2025), led by Medimmune, Glaxo Group, UCL Business; annual filings 2688→3463.
- Medimmune2938
- Glaxo Group1582
- UCL Business1575
- UNIV Oxford Innovation1145
- Glaxosmithkline IP DEV997
- Medical RES Council945
- Cambridge Entpr859
- Kymab850
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.